Iluvien

Type: Product
Name: Iluvien
First reported 2 hours ago - Updated 2 hours ago - 1 reports

FDA Approves First Long-Term Diabetic Macular Edema Treatment

Katie Eder, Senior EditorPublished Online: Tuesday, September 30, 2014Follow Pharmacy_Times:The FDA has approved Alimera Sciences’ fluocinolone acetonide intravitreal implant, Iluvien 0.19 mg, the first long-term treatment for diabetic macular edema (DME) ... [Published Pharmacy Times - 2 hours ago]
First reported Sep 29 2014 - Updated 4 hours ago - 1 reports

Morning Buzz: Exelixis, Inc. (EXEL), Alimera Sciences Inc (ALIM), Dreamworks Animation (DWA)

Shares of Exelixis, Inc. (EXEL) are up almost 23% to $1.91 in pre-market trading Monday after the company announced positive results from coBRIM, the phase 3 pivotal trial of cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination ... [Published Wall Street Pit - Sep 29 2014]
First reported Sep 29 2014 - Updated 5 hours ago - 2 reports

Morning Market Movers

Ambit Biosciences (NASDAQ: AMBI) shares jumped 87.56% to $15.38 after Daiichi Sankyo (OTC: DSNKY) announced its plans to acquire Ambit Biosciences for $15 per share in cash through a tender offer.Athlon Energy (NYSE: ATHL) shares gained 24.67% to $58.26 ... [Published Benzinga.com - Sep 29 2014]
First reported 19 hours ago - Updated 11 hours ago - 1 reports

Lower close as protests continue in Hong Kong

Despite a flurry of merger and acquisition activity, the markets ended lower with the Dow falling 41 points to 17,071 as pro-democracy demonstrations demanded the resignation of Hong Kong chief executive C. Y. Leung. Nasdaq lost 6 points to 4,505On the ... [Published CEOWorld Magazine - 19 hours ago]
First reported Sep 29 2014 - Updated 20 hours ago - 4 reports

Alimera/pSivida's Iluvien Receives FDA Approval for DME

Alimera Sciences, Inc. ’s long wait ended when the FDA finally approved Iluvien for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids. A clinically significant rise in intraocular ... [Published Zacks.com - 20 hours ago]
First reported Sep 29 2014 - Updated 22 hours ago - 1 reports

Alimera Sciences (ALIM) leaps as FDA gives OK

Alimera Sciences (NASDAQ: ALIM) jumped 15.3% to $5.66 after the company confirmed the FDA approval for ILUVIEN. The company expected to begin selling ILUVIEN in the U.S. during the first quarter of 2015. Share volume was 368,000, compared to an all-day ... [Published BayStreet.ca - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 11 reports

Eye Implant Iluvien for Diabetic Macular Edema Clears FDA

(Reuters) - The Food and Drug Administration has approved eye implant Iluvien, from Alimera Sciences and pSivida Corp, for treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did ... [Published Diabetes Care - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

AMBI Snapped Up, ALIM's Iluvien Gets FDA Nod, GLYC Faces Glitch In Study

AbbVie Inc.'s (ABBV: Quote) ongoing phase II study of its investigational compound Veliparib in combination with chemotherapy has demonstrated a 35 percent improvement in progression-free survival and a 30 percent improvement in overall survival in patients ... [Published RTTNews.com - Sep 29 2014]
First reported Sep 26 2014 - Updated Sep 27 2014 - 20 reports

Here’s Why Alimera And pSivida Surged In Extended Trading

Alimera Sciences gained 23% in extended trading on FDA approval for its diabetic macular edema treatment— IluvienPage 1 of 2Published: September 27, 2014 at 8:40 am EST By: Hannah Ishmael Click Ticker to See live coverage ALIM PSDV REGN RHHBYAlimera ... [Published Bidness Etc - Sep 27 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

pSivida Corp. Reports FDA Approval of ILUVIEN(R) -2-

molecules; ability to develop product candidates and products and potential related collaborations; initiation and completion of clinical trials and obtaining regulatory approval of product candidates; continued sales of Retisert; adverse side effects; ... [Published Scottrade - Sep 26 2014]
First reported Sep 09 2014 - Updated Sep 10 2014 - 4 reports

pSivida Corp. Names James Barry to Board of Directors

pSivida Corp. ( NASDAQ: PSDV ) (ASX: PVA), a leader in developingsustained release, drug delivery products for treatment ofback-of-the-eye diseases, announced today that it has elected James J.Barry, Ph.D. to its Board of Directors.Dr. Barry, age 55, ... [Published RCL Advisors - Sep 10 2014]
First reported Sep 03 2014 - Updated Sep 04 2014 - 10 reports

Alimera's ILUVIEN secures Swedish marketing authorization to treat chronic DME

Alimera Sciences has received marketing authorization from the Swedish Medical Products Agency for ILUVIEN to treat vision impairment associated with chronic diabetic macular edema (DME). ... [Published PBR - News - Sep 04 2014]

Quotes

"We rate ALIMERA SCIENCES INC (ALIM) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The area that we feel has been the company's primary weakness has been its disappointing return on equity."
"Corticosteroids have a history of effective use in treating ocular disease inflammation. Iluvien is injected in the back of the patient's eye with an applicator that employs a 25-gauge needle, which allows for a self-sealing wound" according to a company release
"The approval of Iluvien under this broader label brings a DME treatment to the U S that lasts years, not months, after a single injection and greatly expands the addressable market opportunity in the U S " CEO Dan Myers said in a statement
"We are very excited with this news from the FDA and thank the many people who contributed to this outcome and believed in ILUVIEN, including the retinal specialists, clinical site personnel, reading centers, and the many patients and their caregivers for helping us bring this long-term treatment to people in the U S with DME" said Dan Myers

More Content

All (110) | News (67) | Reports (0) | Blogs (43) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
FDA Approves First Long-Term Diabetic Macular E... [Published Pharmacy Times - 2 hours ago]
Lower close as protests continue in Hong Kong [Published CEOWorld Magazine - 19 hours ago]
BARCHART MORNING CALL 9/29 [Published Seeking Alpha - 20 hours ago]
Alimera/pSivida's Iluvien Receives FDA Approval... [Published Zacks.com - 20 hours ago]
Monday's most followed in U.S. including DreamW... [Published Proactive Investors USA - 22 hours ago]
Why Alimera Sciences (ALIM) Stock Is Gaining Today [Published TheStreet.com - 22 hours ago]
Why Alimera Sciences (ALIM) Stock Is Gaining Today [Published The Street Latest - 22 hours ago]
Fourth time's the charm: pSivida, Alimera jump ... [Published MassDevice - Sep 29 2014]
Eye Implant Iluvien for Diabetic Macular Edema ... [Published Diabetes Care - Sep 29 2014]
FDA approves Iluvien for treatment of DME [Published Orthopedics Today - Sep 29 2014]
Will Analysts Start Following Alimera After Its... [Published 24/7 Wall St - Sep 29 2014]
Alimera Sciences Inc Extends Gains On FDA News [Published Benzinga.com - Sep 29 2014]
Will Analysts Start Following Alimera After Its... [Published 24/7 Wall St. - Sep 29 2014]
Alimera Sciences (ALIM) leaps as FDA gives OK [Published BayStreet.ca - Sep 29 2014]
Alimera and pSivida finally win FDA approval fo... [Published FierceBiotech - Sep 29 2014]
BUZZ-U.S. Stocks on the Move-Ambit, Athlon, Ton... [Published Reuters - Sep 29 2014]
Morning Market Movers [Published Benzinga.com - Sep 29 2014]
Morning Buzz: Exelixis, Inc. (EXEL), Alimera Sc... [Published Wall Street Pit - Sep 29 2014]
Benzinga's Top #PreMarket Gainers [Published Benzinga.com - Sep 29 2014]
Alimera Sciences Provides Details On FDA Approv... [Published Pettinga Financial Advisors - Sep 29 2014]
Alimera Sciences Provides Details On FDA Approv... [Published PR Newswire: Policy & Public Interest - Sep 29 2014]
Alimera Sciences wins US FDA approval for ILUVI... [Published Individual.com - Sep 29 2014]
Alimera's ILUVIEN gets FDA approval for diabeti... [Published PBR - News - Sep 29 2014]
US FDA approves Alimera's Iluvien for treatment... [Published PharmaBiz - Sep 29 2014]
Biotech wins US approval for eye treatment [Published NineMSN Finance - Sep 29 2014]
AMBI Snapped Up, ALIM's Iluvien Gets FDA Nod, G... [Published RTTNews.com - Sep 29 2014]
Fourth time lucky for pSivida (The West Austral... [Published West Australian - Sep 29 2014]
Here’s Why Alimera And pSivida Surged In Extend... [Published Bidness Etc - Sep 27 2014]
Alimera Sciences (ALIM) FDA Oks Diabetic Macula... [Published Live-PR.com - Sep 27 2014]
Alimera, pSivida eye implant finally wins U.S. ... [Published DailyMe.Com - Sep 27 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Will Analysts Start Following Alimera After Its... [Published 24/7 Wall St. - Sep 29 2014]
Alimera Sciences traded up big on Monday on news that the company received FDA approval for its diabetic macular edema drug Iluvien. ...
Alimera Sciences Provides Details On FDA Approv... [Published PR Newswire: Policy & Public Interest - Sep 29 2014]
ATLANTA, Sept. 29, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it ...
Alimera's ILUVIEN gets FDA approval for diabeti... [Published PBR - News - Sep 29 2014]
Alimera Sciences has received approval from the US Food and Drug Administration (FDA) for ILUVIEN (fluocinolone acetonide intravitreal implant) to treat diabetic macular edema (DME). ...
Alimera Sciences Receives FDA Approval For ILUV... [Published PR Newswire: Policy & Public Interest - Sep 26 2014]
ATLANTA, Sept. 26, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the ...
pSivida Corp. Reports FDA Approval of ILUVIEN® ... [Published EON Science - Sep 26 2014]
WATERTOWN, Mass.--(EON: Enhanced Online News)--pSivida Reports FDA approval of ILUVIEN for Diabetic Macular Edema - pSivida earns $25 million milestone payment ...
1 2 3 4 5 6 7 8 9
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.